We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

At AC Immune, we are passionate about making a difference in the lives of people affected by Alzheimer’s and other neurodegenerative diseases. Our goal is to become the global leader in personalized treatment of neurodegenerative diseases that are one of the biggest challenges facing society today and future generations.

Latest news

July 7, 2016

AC Immune to receive milestone payment for Anti-Tau Antibody moving into Phase 1 trial for Alzheimer’s disease

May 9, 2016

AC Immune raises USD 43.5 million (CHF 42.7 million) in financing round E

April 18, 2016

AC Immune announces a research and development collaboration in neurodegenerative diseases with Biogen

Company information

Discover more about us, who we are, and how we innovate to improve neurodegenerative disease understanding and develop breakthrough therapies.

Product pipeline

One of the world’s largest Alzheimer’s product pipelines with complementary diagnostic agents driven by proprietary technology platforms.